SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 20, 2014
CANNABIS SCIENCE, INC.
(Exact name of registrant as specified in charter)
| Nevada | 000-28911 | 91-1869677 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 6946 N Academy Blvd, Suite B #254 Colorado Springs, CO | 80918 |
| (Address of principal executive offices) | (Zip Code) |
1.888.889.0888
Registrant’s telephone number
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
|
|
|
|
Item 1.01 Entry into a Material Definitive Agreement
On November 20, 2014, Cannabis Science, Inc.(the “Company”), entered into an Amendment to a License Agreement (the “Amendment Agreement”) that it had entered into with Apothecary Genetics Investments LLC (“Apothecary”) on February 9, 2012 (the “Original Agreement”). The parties entered into the Amendment Agreement to amend certain terms that were contained in the Original Agreement. In the Amendment Agreement, the Company has agreed to issue Apothecary or its assigns 14,500,000 shares of restricted common stock of the Company and fund Apothecary a minimum of $150,000 up to a maximum of $300,000 in working capital per calendar quarter commencing in the quarter ending December 31, 2014. In exchange the Company will purchase and license two northern California production farms with a combined total of 51 acres and related equipment for cannabis cultivation and new product development. As a result of the acquisition, the Company is entitled to licensing fees and royalties, rights to assign assets and fees to affiliates and subsidiaries and ownership of all tangible assets such as land, facilities and equipment as well as new business ventures.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CANNABIS SCIENCE, INC.
| ||
| Date: November 24, 2014 | By: | /s/ Raymond C. Dabney |
|
|
| Raymond C. Dabney, President & C.E.O. |
|
|
|
|
|
|